Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Gaster®D (Famotidine) in Healthy Adults
NCT04123899Phase 1Unknown
- Sponsor
- Dong-A ST
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of famotidine in gastroduodenal ulcer (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 24 hours and Maximum Plasma Concentration at 24 hours. Status: unknown.
02
Drugs
famotidine
03
Conditions
gastroduodenal ulcer
Beyond the preview
Go deeper on NCT04123899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123899.